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Purpose:  Hypoxia  is  a  critical  pathological  factor  in  a  variety  of  retinal  diseases,  including  age-related  macular
degeneration. It upregulates angiogenic growth factors and promotes neovascularization. Hypoxia changes the cellular
redox state and activates class III histone deacetylase sirtuin1 (SIRT1). Activated SIRT1 signals hypoxia inducible factor
(HIF)-2α,  which  transactivates  vascular  endothelial  growth  factor  (VEGF)  and  erythropoietin.  In  this  study,  we
investigated the role of hypoxia induced SIRT1 in choroidal neovascularization in relation to age-related macular
degeneration.
Methods: Choroidal endothelial cells (RF/6A) were maintained in a semiconfluent state and hypoxia was induced by
exposing the cells to cobalt chloride for 24 h. Induction of hypoxia was confirmed by flow cytometric analysis and the
levels of SIRT1 were noted in a hypoxic condition as well in the cells after blocking SIRT1 activity using sirtinol. The
role of SIRT1 in the activation of HIF-2α and nuclear factor–κB (RelA/p65) during hypoxia in the presence or absence
of SIRT1 was assessed using immunoblot analysis. VEGF levels were quantified using enzyme-linked immunosorbent
assay.
Results: Hypoxic induction was confirmed using flow cytometric analysis, which showed cell cycle arrest starting at a
200 µM concentration of cobalt chloride. Hypoxic treatment (200 µM concentration of cobalt chloride) increased SIRT1
levels to 7.8%, which reduced to control level after its activity was  inhibited  (p<0.05).   Activated    SIRT 1  mediates
HIF-2α and nuclear factor-κB (RelA/p65) expression to 4.5 fold and fivefold, respectively, compared to control, and the
levels were suppressed following sirtinol treatment (4.1% and 39.3% respectively; p=0.01). Hypoxic treatment increased
VEGF levels by 94.9±19.6 pg/ml compared to control levels (25.58±3.58 pg/ml). These levels decreased to 10.29±0.2
pg/ml after blocking SIRT1 activity using sirtinol, compared to control (p<0.01).
Conclusions:  Our  study  results  demonstrate  that  hypoxia  mimetic  cobalt  chloride  induces  SIRT1  and  augments
HIF-2α, which activates and releases VEGF.
Ocular neovascularization is associated with a variety of
retinal  diseases  such  as  age-related  macular  degeneration
(AMD),  diabetic  retinopathy,  and  central  retinal  vein
occlusion  [1].  Hypoxia  and  ischemia/inflammation
upregulate angiogenic growth factors such as erythropoietin
(EPO) and vascular endothelial growth factor (VEGF), and
promote neovascularization [2-5]. Regulation of these growth
factors is mediated through the activation of transcription
factors such as hypoxia inducible factor (HIF) [6].
Hypoxia alters the cellular redox state, such as in the
nicotinamide adenine dinucleotide (NAD+/NADH) ratio, and
activates stress responsive deacetylase sirtuin1 (SIRT1), a
class III histone deacetylase (HDAC) [7-9]. SIRT1 activates
HIF-2α and transactivates the downstream genes, including
VEGF and EPO, in hypoxic hepatoma and human embryonic
kidney cells (Figure 1) [7,10,11].
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SIRT1 is expressed in various retinal cells (neural retina,
retinal pigment epithelium, and choroid) [9]. However, its role
has not been evaluated in hypoxic choroidal endothelial cells
(CECs),  the  precursor  of  VEGF-mediated  choroidal
angiogenesis. In this study, we investigated the role of SIRT1
in  choroidal  angiogenesis  in  vitro  and  analyzed  the
mechanism by which SIRT1 may regulate the initiation of
neovascularization.
METHODS
Choroidal endothelial cells (RF/6A; American Type Culture
Collection [ATCC], Manassas, VA) were cultured in minimal
essential  medium  (Thermoscientific,  Logan,  UT)  and  the
media  was  supplemented  with  10%  fetal  bovine  serum
(Invitrogen Corp., Carlsbad, CA), 100 U/ml penicillin, and
100 µg/ml of streptomycin (Invitrogen Corp.). Cells were
maintained at 37 °C in logarithmic scale in a 75 cm2 cell
culture flask.
Induction of hypoxia using cobalt chloride: Hypoxia of
CEC was induced by exposing the cells to cobalt chloride
(Sigma-Aldrich, St. Louis MO) in serum media, as described
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114previously  [12,13],  and  the  induction  was  confirmed  by
cytotoxicity  and  cell  cycle  analysis.  In  brief,  the  dose–
response analysis of cobalt chloride was observed at various
concentrations (100–700 µM) for 24 h and cytotoxicity was
evaluated. Our experiments were performed to evaluate the
interaction between HIF-2α and SIRT1; we exposed our cells
to cobalt chloride for 24 h.
Sirtinol: Sirtinol (2-[[(2-Hydroxy-1-naphthalenyl)meth-
ylene]amino] - N - (1-phenylethyl) benzamide;   C26H22N2O2
    Tocris   Biosciences,   Ellisville,  MO),   a  cell   permeable
  inhibitor of  SIRT1, was  optimized to inhibit sirtuin activity
in parallel experiments.
In vitro cytotoxicity assay: Cell viability was measured
by  WST-1  (4-[3-(4  iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1.3-benzene  disulfonate),  a  colorimetric  assay
based on the cleavage of tetrazolium salts to formazan by
mitochondrial  dehydrogenases  in  viable  cells  (Roche,
Mannheim, Germany). In complete media, 2x103 cells/well
were seeded in 96-well culture plates and maintained to reach
60%–80% confluence (48–72 h) before treatment with cobalt
chloride for 24 h. After treatment, cells were incubated with
WST-1 solution for 2 h at 37 °C. The plates were read at 440
nm  with  a  reference  wavelength  at  630  nm  using  a
multidetection  microplate  reader  (BioTek  Synergy  HT,
Winooski,  VT).  Experiments  were  triplicated  to  achieve
concordance.
Cell  cycle  analysis:  Since  cytotoxicity  of  choroidal
endothelial cells was noted after 300 µM concentrations, we
performed cell cycle analysis to confirm the induction of
hypoxia at 100 and 200 µM concentrations of cobalt chloride.
This analysis was intended to identify the accumulation of
CEC cells in the G2/M phase, giving indirect evidence of
hypoxia in CEC.
Cells  (10×103)  were  plated  on  a  six-well  plate  and
maintained to reach 60%–80% confluence. These cells were
treated  with  cobalt  chloride  at  concentrations  of  100  and
200 µM for 24 h, collected, and washed in ice-cold PBS before
trypsinization, and then diluted to 2.5×105 cells/ml in PBS.
After fixation with 70% ethanol for 2 h, cells were digested
with DNase-free RNase (100 µg/ml) in PBS. Subsequently,
cells were treated with propidium iodide (50 mg/ml in PBS)
and incubated for 30 min at room temperature in the dark for
DNA staining. Flow cytometry was performed on Cytomics
FC  500  (Beckman  Coulter,  Brea,  CA)  with  CXP  V2.2
software. The data were subsequently analyzed with ModFit
for cell cycle determination.
Since the induction of stable hypoxia was confirmed at a
200 µM concentration of cobalt chloride, further experiments
were performed using this concentration; this is referred to as
“hypoxic treatment.”
Deacetylation activity or evaluation of sirtuin1 activity
in cells: To ascertain the role of SIRT1 activity in hypoxic
choroidal endothelial cells, intracellular SIRT1 activity was
evaluated using an HDAC fluorimetric cellular activity kit
(Enzo Life Sciences, Plymouth meeting, PA). This assay is
based on cell-permeable Fluor de Lys substrate, which is
deacetylated by SIRT1 and yields the deacetylated form of
Fluor de Lys substrate, a process dependent on the presence
of SIRT1 in the cells. Cells (10×103) were grown on a 96-well
microtiter  plate  and  treated  with  hypoxia  (200  µM
concentration of hypoxia mimetic cobalt chloride) for 24 h.
They were then incubated with 200 µM Fluor de Lys substrate
Figure 1. Schematic representation of
sirtuin1  role  in  neovascularisation.
During  hypoxia  sirtuin1  (SIRT1)
activates,  that  binds  and  transactivate
hypoxia inducible factor (HIF)-2α and
release  vascular  endothelial  growth
factor (VEGF).
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115in the presence of 1 µM trichostatin (TSA) at 37 °C, for 4−5
h. The reaction was terminated by adding an ice-cold cell lysis
buffer  containing  Fluor  de  Lys  Developer  (Enzo  Life
Sciences) and 2 mM nicotinamide. Experimental “Time 0”
controls were prepared by adding Fluor de Lys substrate with
1 µM TSA and Fluor de Lys Developer (Enzo Life Sciences)
with 2 mM nicotinamide immediately to the cell culture plate.
Plates were incubated for an additional 15 to 30 min at 37 °C.
Fluorescence  was  determined  by  reading  on  a  microplate
reader (BioTek Synergy HT) with an excitation wavelength
of  360  nm  and  an  emission  wavelength  of  460  nm,  and
measured  as  an  arbitrary  fluorescence  unit  (AFU).  The
aforementioned  experiment  was  repeated  in  presence  of
sirtinol (200 µM), a competitive inhibitor of SIRT1 activity,
to confirm the role of SIRT1 in hypoxia. The levels of SIRT1
were  normalized  against  control  and  expressed  as
percentages.  Experiments  were  repeated  three  times  for
concordance.
Preparation of cytosolic and nuclear protein fractions:
To determine the SIRT1-mediated expression of HIF-2α and
the  activation  of  proinflammatory  cytokine  nuclear  factor
(NF)-κB in hypoxic CEC cells, we isolated cytosolic and
nuclear protein fractions. Cells (2.5×105) were plated in a 75
cm2 culture flask and maintained in an appropriate condition.
After  hypoxic  treatment  (200  µM  concentration  of  cobalt
chloride),  cells  were  scraped  off  from  the  flask  and
resuspended in 20 ml of Hank’s balanced saline solution and
spun at 200× g at 0 °C for 10 min. Cells were washed with
Hank’s balanced saline solution followed by spinning at 200×
g at 0 °C for 10 min. Cells were suspended in 2 ml of nuclear
wash buffer (10 mM HEPES, pH 8.0; 50 mM NaCl, 15%
sucrose, 0.1 mM EDTA, 0.5% Triton X-100, 1 mM DTT,
5 mM MgCl2, and 1 mM phenylmethylsulfonyl fluoride) and
incubated for 10 min at 0 °C. To isolate the cytoplasmic
fraction, this cellular suspension was loaded onto 2 ml, 30%
sucrose  cushion  in  nuclear  wash  buffer  (without  Triton
X-100).  To  isolate  the  nuclear  fraction,  following
centrifugation at 1,400× g for 30 min (at 0 °C), the pellets were
dissolved with a lysis buffer containing 10 mM HEPES, pH
8.0; 600 mM NaCl, 10 mM MgCl2, 0.1 mM EDTA, 1 mM
DTT, and 5 mM spermidine for 60 min and then centrifuged
at  16,000×  g  for  10  min  (at  4  °C).  All  the  fractionation
procedures were completed on ice.
Immunoblot  analysis:  Protein  concentrations  of  the
prepared cytosolic and nuclear extracts were evaluated using
Bradford  assay  solution  (Biorad,  Hercules,  CA).  Twenty
micrograms of protein samples were run on 8% SDS–PAGE
gel and transferred to nitrocellulose membranes, which were
blocked in PBS-Tween-20 (PBST) with 5% skimmed milk at
4 °C. The membranes were incubated with primary antibodies
for HIF-2α (1:1,000; Abcam, Cambridge, MA) and RelA/p65
of NF-κB (1:2,000; Invitrogen Corporation) in PBS at 4 °C
overnight. After washing with PBST, the blots were incubated
with  horseradish  peroxidase-conjugated  antirabbit  IgG
antibodies at a 1:1,000 dilution for 2 h at room temperature.
Blots were washed three times in PBST and the proteins were
detected  with  the  enhanced  chemiluminescence  method.
Bands  were  scanned  and  densitometry  was  performed  to
quantify  the  intensity  of  signal  using  ImageJ  analysis
software. The protein levels were expressed as percentages.
Vascular  endothelial  growth  factor  enzyme-linked
immunosorbent  assay:  We  tested  whether  SIRT1  was
involved in induction of angiogenesis through hypoxia by the
activation of VEGF. VEGF protein that was released into the
conditioned  media  was  measured  using  enzyme-linked
immunosorbent assay (ELISA) after plating 1×105 cells on a
six-well culture plate. After treatment, the cell culture media
was collected after 24 h of hypoxic treatment at 5% CO2 at
37 °C. The concentration of VEGF in the media was measured
with an ELISA kit (Invitrogen Corporation) according to the
manufacturer’s instructions. The aforementioned experiment
was repeated after blocking SIRT1 activity using sirtinol.
These  VEGF  levels  were  analyzed  for  correlation  to
fluorescence  levels  (AFU)  of  SIRT1.  Experiments  were
repeated three times for concordance.
Statistics:  Mean  and  standard  deviations  (SD)  of  3
independent experimental results of each in triplicate were
analyzed using GraphPad Instat software (GraphPad Instat3,
LaJolla, CA). Means were compared using the two-tailed,
unpaired or paired Student t test. The correlation between
SIRT1  and  VEGF  values  was  analyzed  using  Pearson's
correlation coefficient. Statistical significance was accepted
for p values of less than 0.05.
RESULTS
Induction of hypoxia: Cobalt chloride treatment did not induce
cytotoxicity at doses lower than a concentration of 300 µM,
as inferred from WST-1 analysis. At low doses of hypoxia
mimetic cobalt chloride (100 and 200 µM), increases in cell
viability  of  106.0%  and  110.0%  were  noted  compared  to
control cells (p=0.29). At progressively higher doses (300,
400, and 500 µM), cell viability proportionally declined to
102.4%,  98.3%,  and  67.0%,  respectively,  compared  to
control. We observed 51.7% viability (effective dose [ED]50)
at a 600 µM concentration of cobalt chloride; this decreased
further to 38.6% at a concentration of 700 µM (Figure 2A).
The DNA analysis revealed that 79.65% of control cells
were at G0/G1, 20.35% in the S-phase and none of them at the
G2/M phase. At a 100 µM concentration of cobalt chloride,
the proportion of cells decreased to 56.7% at the G0/G1 phase,
37.39%  at  the  S-phase,  and  5.9%  at  the  G2/M  phase.  At
200 µM, 51.84% cells at the G0/G1 phase, 37.54% at the S-
phase, and 10.62% at the G2/M phase was noted (Figure 2B).
As the hypoxic challenge mediated through the exposure to
cobalt chloride increased, a twofold increase in the proportion
of S-phase and G2/M phase cells (20.35% to 48%) was noted,
which is indirect evidence of the degree of hypoxia (p<0.05).
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116Hypoxic treatment induced activation of sirtuin1: In hypoxic
cells (200 µM concentration of cobalt chloride), SIRT1 levels
increased to 7.8% compared to control. The increase was not
statistically significant in comparison to control cells (p=0.4).
However,  after  inhibition  with  sirtinol,  the  SIRT1  level
decreased  31.6%  compared  to  control.  The  reduction  in
SIRT1 levels was statistically significant compared to control
cells (p<0.05; Figure 3).
Increased  expression  of  hypoxia  inducible  factor–2α  and
RelA/p65 (nuclear factor–κB) by sirtuin1: We evaluated the
SIRT1-mediated activation of HIF-2α and proinflammatory
cytokine NF-κB in the treated cells. The HIF-2α and NF-κB
protein  levels  were  quantified,  normalized,  and  compared
against control. In comparison to control cells, we observed
a4.5  fold  (451%)  increase  of  HIF-2alpha  expression  in
hypoxia-treated cells (200 uM concentration). However, the
HIF-2α levels decreased to 4.1% in hypoxia-treated cells after
exposed to sirtinol (200 µM). This suppression of HIF-2α
expression  following  the  blockage  of  SIRT1  activity  was
observed to be statistically significant (p<0.01; Figure 4).
SIRT1 may activate the proinflammatory pathway via the
activation  of  RelA/p65  subunit  of  NF-κB  under  hypoxic
treatment. In comparison to control cells, we noted a 5.4 fold
(542%) increase in the expression of NF-κB (p65) in hypoxic
CEC.  This  expression  decreased  to  39.3%  after  blocking
SIRT1 activity in hypoxia-treated cells (p<0.01; Figure 4).
Sirtuin1-mediated activation of vascular endothelial growth
factor through hypoxia: We measured VEGF (121 and 165)
in  the  conditioned  media  of  treated  cells  that  showed
94.9±19.6 pg/mL after the induction of hypoxic treatment
(200  µM  concentration)  compared  to  a  control  level  of
25.58±3.58 pg/ml. After blocking SIRT1 activity, the VEGF
level decreased to 10.29±0.2 pg/ml. This reduction in VEGF
level in hypoxia-treated cells after blocking SIRT1 activity
was statistically significant compared to control (Figure 5A;
p<0.05). In addition, as the SIRT1 increases, VEGF levels
linearly correlated in these treatment conditions (Figure 5B;
r=0.68).
DISCUSSION
AMD, a common cause of blindness after the age of 65, is
characterized by either the presence of drusen (dry AMD) or
VEGF-induced choroidal endothelial cell proliferation with
associated  leakage  (exudative  AMD)  [14].  In  exudative
AMD, chronic hypoxia (through HIF-1 and 2) initiates VEGF
release and induces choroidal endothelial cell proliferation, an
initial step in the formation of choroidal neovascularization.
The mechanism of interaction between HIF and the proteins/
factors that translate these signals through downstream genes
is  not  well  defined.  Characterizing  these  interactions  and
identifying  the  role  of  associated  factors  are  vital  for  the
development of novel therapies that target hypoxia-induced
neovascularization.
Figure 2. Evaluation of cobalt chloride
induced cytotoxicity and the induction
of hypoxia. A: Hypoxia-induced growth
arrest  by  cobalt  chloride  at  various
concentrations  (100–700  µM)  in
choroidal  endothelial  cells;  the
concentration of cobalt chloride used for
inducing hypoxia is represented on the
x-axis and the percentage of viable cells
normalized  against  control  on  the  y-
axis. B: The effects of hypoxia induced
by  cobalt  chloride  on  the  cell  cycle.
Choroidal  endothelial  cells  (CECs)
were  treated  with  cobalt  chloride  at
various concentrations (0 µM, 100 µM,
200 µM) for 24 h and analyzed for DNA
content;  representative  data  are
displayed. (Mean+SE; n=3; *p<0.05).
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117Histone acetylation and deacetylation play a critical role
in  cellular  events,  including  gene  expression  and
inflammation  [15-17].  Acetylation  of  conserved  lysine
residues in the histone tail (by histone acetyl transferases)
relaxes  the  histone-histone  and  histone-DNA  interaction,
facilitates transcription factor access to DNA, and enhances
gene expression. Deacetylation (by HDACs) suppresses gene
expression through the promotion of chromatin condensation
[18].
One HDAC member, SIRT1, promotes cell survival by
inhibiting stress-induced apoptosis [7,9]. It activates number
of proteins like VEGF, EPO, FOXO, p53, and NF-κB [5,
15-17]. Silencing SIRT1 activity induces growth arrest and/
or apoptosis in human epithelial cancer cells [19], as well as
cisplatin-resistant cancer cells [20]. Cambinol, an inhibitor of
SIRT1 and SIRT2, promotes apoptosis Burkitt lymphoma
xenografts in mice [21]. In Hep3B and HEK293 cells, during
hypoxia, SIRT1 deacetylates HIF-2α and increases VEGF
expression [5,22]. SIRT1 is expressed in the cornea, ciliary
body, lens, retinal pigment epithelium, choroid, and neural
retina of mice [9].
In our study, we evaluated the role of SIRT1 in hypoxic
choroidal endothelial cells. We induced hypoxia in choroidal
endothelial  cells  with  cobalt  chloride.  Under  normoxic
Figure 3. Evaluation of sirtuin1 levels at
the cellular level. Choroidal endothelial
cells (CECs) were cultured in a 96-well
microtiter plate and treated with hypoxia
for 24 h. Sirtuin1 (SIRT1) levels were
evaluated  in  hypoxic  cells  with  or
without SIRT1 activity being blocked
using  sirtinol  (Mean+SE;
n=3;*p<0.05). The x-axis represents the
experimental conditions and the y-axis
represents  the  SIRT1  levels  in
percentage  (normalized  against
control).
Figure 4. Immunoblot shows hypoxia
inducible factor (HIF)-2α and the p65
subunit of nuclear factor κB (NF-κB)
protein  expression  in  the  nuclear
extracts  of  choroidal  endothelial  cells
during  hypoxic  condition  induced  by
cobalt  chloride.  The  histogram
represents densitometric evaluation of
respective  protein  expression.
Choroidal endothelial cells were treated
with hypoxia (200 µM concentration of
cobalt  chloride)  in  the  presence  and
absence of sirtinol (200 µM). Mean+SE;
n=3;*p<0.01.
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118conditions,  HIF  proteins  are  continuously  degraded  by
binding to the oxygen-dependent degradation domain through
ubiquitinylation. Within the oxygen-dependent degradation
domain,  prolyl  hydroxylase  enzymes  hydroxylate  specific
proline residues and initiate degradation. Cobalt removes the
iron-binding center of the prolyl hydroxylase enzyme, mimics
cellular hypoxia, and increases HIF concentration [3,23]. In
our study, we observed a hypoxic induction at a 200 µM
concentration of cobalt chloride, where flow analysis showed
an increase in S and G2/M arrest. In transformed cells (mouse
embryonic  fibroblasts,  human  gastric  carcinoma  cells)
hypoxia predominantly arrests cells in the S and G2/M-phase
[23,24].
After induction of hypoxia with cobalt chloride in CEC,
we measured SIRT1 levels and compared them to controls.
SIRT1 levels were higher in hypoxic cells (1.1 fold) compared
to controls (10.25±1.8 AFU; 9.25±1.0 AFU). The role of
SIRT1 in hypoxia was confirmed by inhibiting its activity
using sirtinol, a chemical inhibitor that selectively inhibits
Sir2p  transcriptional  activity  [25].  After  treatment  with
sirtinol, levels of SIRT1 declined to 6.5±1.5 AFU compared
to 10.25±1.8 AFU in hypoxia-treated cells (Figure 3).
SIRT1  activates  HIF-2α  by  binding  to  its  C-terminal
domain through deacetylation [5]. The activation of HIF-2α
was evaluated by assessing HIF-2α protein expression after
induction of hypoxia. HIF-2α expression increased to 0.325
optical  density  units  (ODU;  4.5  fold)  in  hypoxic  cells
compared to controls (0.072 ODU; p<0.05). After inhibition
with  sirtinol,  HIF-2α  expression  decreased  further  (0.003
ODU)  and  confirmed  correlation  between  SIRT1  and
HIF-2α.
SIRT1 regulates the VEGF-A promoter through HIF-2α
deacetylation [5]. Based on our results, we hypothesize that
elevated  SIRT1  levels  that  result  from  hypoxic  challenge
activate HIF-2α and promote VEGF transcription. Increased
VEGF  levels  after  hypoxia  in  the  present  study  and  the
subsequent decrease after inhibiting SIRT1 activity establish
a causal relation between SIRT1 and HIF-2α.
Additionally, in this study, we observed the activation of
inflammatory proteins by SIRT1. Activation/deacetylation of
the RelA/p65 subunit of NF-κB (at lysine 310) by SIRT1 can
transactivate  NF-κB-dependent  proinflammatory  cytokines
[26,27]. In our study, expression of RelA/p65 increased to
0.179 ODU (5.4 fold) in hypoxic cells compared to controls
(0.033  ODU).  After  inhibition  with  sirtinol,  RelA/p65
expression was decreased (0.013 ODU); this confirmed the
inflammatory role of SIRT1.
In conclusion, our study results demonstrate that hypoxia
initiates SIRT1 and augments HIF-2α, which in turn activates
and  releases  VEGF.  Our  study  identifies  SIRT1  as  an
important functional key in determining the cell fate of CECs
in hypoxia.
Figure  5.  Sirtuin1  (SIRT1)  induced
vascular  endothelial  growth  factor
(VEGF)  release.  A:  Evaluation  of
VEGF levels in the conditioned media
after  the  exposure  of  choroidal
endothelial cells with hypoxia with or
without blocking SIRT1 activity (200
uM sirtinol; mean+SE; n=3; *p<0.05)
using  enzyme-linked  immunosorbent
assay  (ELISA).  The  x-axis  represents
the experimental conditions and the y-
axis represents the VEGF protein levels
in pg/ml. B: Correlation of SIRT1 levels
measured in the presence of escalating
VEGF.  The  x-axis  represents  the
observed mean VEGF protein levels in
pg/mL  and  y-axis  represents  their
respective SIRT1 levels.
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